Cocrystal Pharma, Inc. (COCP) News
Filter COCP News Items
COCP News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
COCP News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest COCP News From Around the Web
Below are the latest news stories about COCRYSTAL PHARMA INC that investors may wish to consider to help them evaluate COCP as an investment opportunity.
COCP: Phase 2a Trial of CC-42344 Extended…By David Bautz, PhD NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT Business Update Phase 2a Trial of CC-42344 Extended On December 31, 2024, Cocrystal Pharma, Inc. (NASDAQ:COCP) announced that the Phase 2a clinical trial of its oral PB2 inhibitor, CC-42344, will be extended due to unexpectedly low infection rates among trial participants that were challenged with a H3N2 influenza strain. The |
Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral InfectionsData show favorable safety and tolerability with dosing up to 800 mg for 10 daysPlans to initiate human challenge study in 2025 in norovirus-infected subjects BOTHELL, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces favorable safety and tolerability results at dosing up to 800 mg per day for 10 consecutive days from the multiple-ascending dose (MAD) portion of the ongoing Phase 1 study with its oral protease inhibitor CDI-98 |
Cocrystal to extend enrolment in Phase IIa influenza inhibitor trialThe company reported the enrolment of the trial’s first subject in December 2023. |
Cocrystal Pharma Shares Drop 35% Following Phase 2a Study Extension AnnouncementAntiviral medicines are developed using a unique structure-based drug discovery platform. |
Top Midday DeclinersSangamo Therapeutics (SGMO) shares plunged 55%, a day after the company said its partner, Pfizer (PF |
Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344Data support favorable safety and tolerability profile with no serious adverse events (SAEs) or study-related drug discontinuationsEnrollment to be extended due to low influenza infection among challenged participants; virology results are uninterpretable BOTHELL, Wash., Dec. 31, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces plans to extend enrollment in the Phase 2a human challenge study with its investigational, broad-spectrum, oral inf |
US Penny Stocks To Watch In December 2024As the Federal Reserve's meeting on interest rates takes center stage, the U.S. markets are experiencing a mix of anticipation and caution, with indices like the Dow Jones facing consecutive declines while others hit record highs. The term 'penny stocks' might feel like a relic of past market eras, but the potential they represent is as real as ever. Typically referring to smaller or relatively new companies, these stocks can provide a mix of affordability and growth potential when paired... |
COCP: Multiple Upcoming Catalysts…By David Bautz, PhD NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT Business Update Multiple Upcoming Catalysts Cocrystal Pharma, Inc. (NASDAQ:COCP) has multiple upcoming catalysts over the next few months as it develops CC-42344 as a treatment for influenza and CDI-988 as a treatment for both coronavirus and norovirus infections. Before the end of 2024, we expect Cocrystal to report topline |
November 2024 US Exchange Standouts: Promising Penny StocksAs the U.S. stock market navigates a "sometimes-bumpy path" toward its inflation target, as noted by Fed Chair Jerome Powell, investors are closely watching for opportunities amidst fluctuating indices. Penny stocks, though an older term, remain relevant by highlighting smaller or less-established companies that can offer substantial value. By focusing on those with strong financials and clear growth potential, investors may find promising opportunities within this often-overlooked segment of... |
Cocrystal Pharma Reports Third Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsBOTHELL, Wash., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three and nine months ended September 30, 2024, and provides updates on its antiviral product pipeline, upcoming milestones and business activities. “The coming months are critically important to Cocrystal as we expect to report topline results from two ongoing clinical studies with our best-in-class antiviral candidates in major medical indicat |